Website intended for a NZ health professional readership
Media Statement from Heather Verry, CEO Diabetes NZ
Response to PHARMAC update on proposal to fund two new medicines for type 2 diabetes
Diabetes New Zealand is disappointed that PHARMAC is delaying the decision on funding type 2 diabetes medicines empagliflozin and dulaglutide. However, we recognise that they are taking the time to carefully consider the substantial feedback on the proposal received from individuals, professional societies and advocacy groups.
We are pleased that PHARMAC is taking into consideration our concerns about improving equity of access to the new medications, and keen to see our feedback being part of the review process. Diabetes New Zealand is strongly committed to seeing more diabetes drugs funded to improve health outcomes for all New Zealanders with diabetes.
Pharmacist prescribers Linda Bryant and Leanne Te Karu discuss positive polypharmacy for heart failure. Current evidence shows the intensive implementation of four medications offers the greatest benefit to most patients with heart failure, with significant reductions in cardiovascular mortality, heart failure hospitalisations and all-cause mortality
